|
Review
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
Kyung-Ann Lee, Hae-Rim Kim, So Young Yoon
Korean J Intern Med. 2019;34(6):1197-1209. Published online April 25, 2019
Immune checkpoint inhibitors (ICIs) have revolutionized anticancer therapy due to their long-term clinical benefits and immune boosting mechanisms. However, despite their consistent therapeutic effects, the use of ICIs is associated with a spectrum of adverse events due to their autoimmune and auto-..
|
|
|
Cardiology / Original Article
The incidence and predictors of overall adverse effects caused by low dose amiodarone in real-world clinical practice
Hack-Lyoung Kim, Jae-Bin Seo, Woo-Young Chung, Sang-Hyun Kim, Myung-A Kim, Joo-Hee Zo
Korean J Intern Med. 2014;29(5):588-596. Published online August 28, 2014
Background/Aims: Most current knowledge regarding amiodarone toxicity derives from clinical trials. This study was performed to investigate the incidence and risk factors of overall adverse effects of amiodarone in real-world practice using a large sample size.
Methods: Between January 1, 2000 and ..
|
|
|
|
|
Original Article
Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
Kyu-Hyoung Lim, Ho-Il Yoon, Young Ae Kang, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jae Ho Lee, Choon-Taek Lee, Jong Seok Lee
Korean J Intern Med. 2010;25(1):86-92. Published online February 26, 2010
Background/AimsThe aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymph..
|
|
|
